Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06707610 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Advanced Cancer, sponsored by Shanghai Allink Biotherapeutics Co..

Recruiting
Registry status
Phase 1
Development phase
234
Enrollment target
4
Study locations

NCT06707610 is a Phase 1 study of Advanced Solid Tumor and Advanced Cancer that is actively recruiting participants, run by Shanghai Allink Biotherapeutics Co.. The registered enrollment target is 234 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% higher). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06707610, a Phase 1 study of Advanced Solid Tumor and Advanced Cancer, is actively recruiting participants, sponsored by Shanghai Allink Biotherapeutics Co..

RECRUITING
Registry status
Phase 1
Development phase
234 participants
Enrollment target
4
Study locations

Study Summary

TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK202.

Conditions Studied

Advanced Solid Tumor Advanced Cancer

Interventions

  • DRUG ALK202

Study Locations (4)

New South Wales

  • Scientia Clinical Research Ltd - Randwick
  • Macquarie University - Sydney

Florida

  • D&H Cancer Research Center Llc - Margate

Virginia

  • Next Oncology - Fairfax

Trial Details

FieldValue
Enrollment Target 234 participants
Start Date 2025-02-10
Est. Completion 2028-12
Phase Phase 1

Sponsor

Shanghai Allink Biotherapeutics Co.

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06707610

The ClinicalTrials.gov registry entry for NCT06707610 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% higher). The listed sponsor is Shanghai Allink Biotherapeutics Co., which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ALK202 is the first listed.

NCT06707610 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New South Wales, Florida, Virginia.

Frequently Asked Questions

What is clinical trial NCT06707610 about?

NCT06707610 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors". TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The st...

What is the current status of trial NCT06707610?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 234 participants. The study started on 2025-02-10. Estimated completion is 2028-12.

What conditions does trial NCT06707610 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Advanced Cancer.

What interventions are being tested in trial NCT06707610?

The interventions under investigation include: ALK202 (DRUG).

Who is sponsoring clinical trial NCT06707610?

This trial is sponsored by Shanghai Allink Biotherapeutics Co., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06707610 being conducted?

This trial has 4 study locations across Florida, Virginia, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Advanced Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.